These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 25317818)

  • 1. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
    Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
    JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
    Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
    J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
    J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
    Goyal A; Hordinsky M; Lazaryan A
    Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
    Nevet MJ; Zuckerman T; Sahar D; Bergman R
    Am J Dermatopathol; 2015 Jan; 37(1):73-7. PubMed ID: 25548993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.
    Corbin ZA; Nguyen-Lin A; Li S; Rahbar Z; Tavallaee M; Vogel H; Salva KA; Wood GS; Kim YH; Nagpal S
    J Neurooncol; 2017 May; 132(3):439-446. PubMed ID: 28271282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.
    Hirai Y; Sakurai J; Yoshida S; Kikuchi T; Mitsuhashi T; Miyake T; Fujimura T; Abe R; Fujikawa H; Boki H; Suga H; Shibata S; Miyagaki T; Shimauchi T; Kiyohara E; Kawakami Y; Morizane S
    J Dermatol; 2024 Aug; 51(8):1037-1049. PubMed ID: 38874430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycosis fungoides/Sézary syndrome: report of an unusual case.
    Mehta A; Dhungel BM; Khan MF
    J Cutan Pathol; 2006 Sep; 33 Suppl 2():12-5. PubMed ID: 16972946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
    Janiga J; Kentley J; Nabhan C; Abdulla F
    Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model.
    Wang Z; Ma J; Zhang H; Ramakrishna R; Mintzlaff D; Mathes DW; Pomfret EA; Lucia MS; Gao D; Haverkos BM; Wang Z
    FEBS Open Bio; 2023 Jul; 13(7):1309-1319. PubMed ID: 37157185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
    Kamijo H; Miyagaki T
    Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.
    Muniesa C; Gallardo F; García-Doval I; Estrach MT; Combalia A; Morillo-Andújar M; De la Cruz-Vicente F; Machan S; Moya-Martínez C; Rovira R; Sanchez-Gonzalez B; Acebo E; Amutio E; Peñate Y; Losada-Castillo MDC; García-Muret MP; Iznardo H; Román-Curto C; Cañueto J; Fernández-de-Misa R; Flórez Á; Izu RM; Torres-Navarro I; Zayas A; Pérez-Paredes G; Blanes M; Yanguas JI; Pérez-Ferriols A; Callejas-Charavia M; Ortiz-Romero PL; Pérez-Gil A; Prieto-Torres L; González-Barca E; Servitje O
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):57-64. PubMed ID: 36017748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin in CD30
    Enos TH; Feigenbaum LS; Wickless HW
    Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
    Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
    Photiou L; van der Weyden C; McCormack C; Miles Prince H
    Curr Oncol Rep; 2018 Mar; 20(4):32. PubMed ID: 29572582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome: a concise review.
    Johnson WT; Mukherji R; Kartan S; Nikbakht N; Porcu P; Alpdogan O
    Chin Clin Oncol; 2019 Feb; 8(1):12. PubMed ID: 30525754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.
    Shono Y; Suga H; Kamijo H; Fujii H; Oka T; Miyagaki T; Shishido-Takahashi N; Sugaya M; Sato S
    Acta Derm Venereol; 2019 Jul; 99(9):809-812. PubMed ID: 31045236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-stage mycosis fungoides in palmoplantar localization with large-cell transformation and partial CD30 expression shows complete response to brentuximab vedotin.
    Pham AK; Carter JB; Ratcliffe NR; Fuld AD; Lansigan F; Burnside NJ; Guill MA; Zug KA; Jarvis LA; LeBlanc RE
    J Cutan Pathol; 2018 Jun; 45(6):458-462. PubMed ID: 29512830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.